Changes in Sexual Orientation During Gender-Affirming Hormone Therapy
The provided evidence does not document changes in sexual orientation as an outcome of gender-affirming hormone therapy. Sexual orientation is not addressed in the Endocrine Society clinical practice guidelines 1 or in contemporary research on hormone therapy outcomes 2.
What the Evidence Actually Shows
The available guidelines and research focus on:
Physical and Psychological Changes Documented
- Physical feminization/masculinization including breast development, body composition changes, muscle mass alterations, and secondary sex characteristic changes 1, 2
- Psychological well-being improvements are noted with hormone therapy, but these relate to gender dysphoria relief and mental health outcomes—not sexual orientation 1
- Personality trait changes have been studied, showing decreased neuroticism in testosterone-treated individuals and increased emotional openness in estrogen-treated individuals 3, but these are distinct from sexual orientation
Why Sexual Orientation Is Not Discussed
Sexual orientation is understood to be established during prenatal development through hormonal and genetic factors 4. The research indicates that prenatal hormone exposure influences sexual orientation, not adult hormone administration for gender-affirming care.
Common Misconception to Avoid
There is no clinical evidence that gender-affirming hormone therapy in adults changes sexual orientation. What may appear as "changes" are often:
- Individuals feeling more comfortable expressing their authentic attractions after transition
- Shifts in how individuals label their orientation as their gender identity aligns with their presentation
- Greater comfort exploring relationships that were previously avoided due to gender dysphoria
What Is Actually Monitored
The Endocrine Society guidelines 1 recommend monitoring:
- Hormone levels (testosterone 320-1000 ng/dL for FTM; estradiol ~200 pg/mL and testosterone <55 ng/dL for MTF)
- Physical changes in secondary sex characteristics
- Psychological well-being and persistence of gender dysphoria
- Adverse effects like thromboembolism risk, particularly with estrogen therapy
Sexual orientation is neither a target outcome nor a monitored parameter in gender-affirming hormone therapy protocols.